RNS . News to drop Submission of CTA for AVA6000 Pro-doxorubixin9 Feb 2021 13:09
We should get an update very soon. From RNS Wed, 23rd Dec 2020 07:00
"We expect to receive feedback from the MHRA (Medicines and Healthcare products Regulatory Agency) on the Clinical Trial Application by February 2021. Dosing of first patients will commence when we have responded to that feedback and received approval to proceed. I look forward to updating the market on the detailed timing in due course."
"significant clinical and commercial value in a chemotherapy market that is expected to grow to $56 billion by 2024."